TOP STORIES

• REGULATORY Japan Approves Label Expansions for Braftovi, Augtyro, Uplizna, and More
  November 21, 2025

• REGULATORY Providers Push to Expand 2% Buffer Zone in Drug Price Revisions as Costs Rise
  November 20, 2025

• REGULATORY Japan Moves to Advance “G1” Price Cuts by 5 Years under Proposed LLP Overhaul
  November 20, 2025

• BUSINESS Boehringer Sees Oncology as Pillar of Japan Business, Starting with Hernexeos
  November 20, 2025

• ORGANIZATION PhRMA Chief Warns Japan Is Losing Its Appeal, Urges End to On-Patent Price Cuts
  November 19, 2025

• BUSINESS Japan’s Big 4 Wholesalers Lower Operating Margin as COVID-19 Windfall Recedes
  November 18, 2025

• REGULATORY Japan Launches Pilot Expert Committee System for Patent Linkage Reviews, Aims to Reduce IP Feuds
  November 17, 2025

• COMMENTARY MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
  November 17, 2025

• REGULATORY Chuikyo Split over Higher Copays under LLP Scheme; Payer Push Meets Provider Caution
  November 17, 2025

• BUSINESS Fuji Stresses No Supply Impact, Denies Patent Allegations over Eylea Biosimilar
  November 17, 2025

• REGULATORY Elrexfio to Escape CEA-Based Price Tweak, Analysis to Resume for Paxlovid
  November 17, 2025

• BUSINESS Novartis Overhauls Sales Model to Prioritize Solving Regional Treatment Gaps
  November 14, 2025

• REGULATORY Nipro-Samsung Alliance Nears First Approval in Japan with Stelara Biosimilar
  November 14, 2025

• REGULATORY Japan Panel to Review KalVista’s Oral HAE Drug, GSK’s Asthma Med, and More on Nov. 27
  November 14, 2025

• BUSINESS Keytruda Again Tops Japan Market in July-September: IQVIA
  November 14, 2025

• BUSINESS Bayer, Regeneron Move to Block Fuji’s Newly Listed Eylea Biosimilar in Japan
  November 13, 2025

• REGULATORY LDP Study Group Seeks Uniform 5% Drug Price Hike, Warns of US MFN Spillover
  November 12, 2025

• BUSINESS J&J Japan Targets Top Share in Key Disease Areas by 2030: New President
  November 12, 2025

• REGULATORY Japan’s 1st Biosimilars for Eylea, Actemra Get NHI Listing in November
  November 11, 2025

• REGULATORY MOF Pushes Stronger Use of CEA for Pricy Meds towards FY2026 Budget
  November 11, 2025

ページ

• « 先頭
• ‹ Prev
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »